

**REQUEST FOR QUOTATION (091-2025-GAVI-RFQ)**

|  |  |  |
| --- | --- | --- |
| Request for Quotation for an Evaluability Assessment for the end-line impact evaluation of the African Vaccine Manufacturing Accelerator (AVMA) | | |
|  |  |  |
| RFQ Opening Date: 09 July 2025 |  | RFQ Closing Date: 11 August 2025 |
|  |  |  |
| Address responses via email to [procurement@gavi.org](file:///C:/Users/mwattinger/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/ILKZ9D01/procurement@gavi.org) | | |

**Background and Introduction:**

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world’s children against some of the world’s deadliest diseases. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organisations that fund Gavi’s work here. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1 billion children – and prevented more than 17.3 million future deaths, helping to halve child mortality in 78 lower-income countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation, above all the zero-dose children who have not received even a single vaccine shot. The Vaccine Alliance employs innovative finance and the latest technology – from drones to biometrics – to save lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency.

Learn more at [www.gavi.org](http://www.gavi.org).

**Objective:**

Gavi Alliance (“Gavi”), invites  bidders (herein after called “Bidder” or “Bidders”)  to submit offers, consisting of a technical and a financial offer, together with any supporting documents (herein after called the “Proposal” or “Proposals”) for the provision of the requirements defined in this RFQ document: **091-2025-GAVI-RFQ Evaluability Assessment for the end-line impact evaluation of the African Vaccine Manufacturing Accelerator (AVMA).**

**Gavi Project:**

The project is to undertake an evaluability assessment (EA) for an endline evaluation of the contribution, outcomes and impact of the African Vaccine Manufacturing Accelerator (AVMA). This EA is expected to build upon the Board-approved AVMA Monitoring, Evaluation and Learning (MEL) framework.

African Vaccine Manufacturing Accelerator (AVMA)

* The African Vaccine Manufacturing Accelerator (AVMA) is a financing mechanism established to make up to US$ 1.2 billion available over ten years commencing with AVMA’s launch in June 2024 to accelerate the expansion of commercially viable vaccine manufacturing in Africa.
* AVMA offers a ‘pull financing mechanism’ by providing downstream incentives to manufacturers to help offset initial costs of development and production.
* The instrument was approved by the Gavi Board in December 2023 and launched in June 2024, following a design process conducted over nearly two years of close collaboration between Gavi, the African Union and the Africa Centers for Disease Control and Prevention (Africa CDC), with extensive consultations with partners, donors, industry, civil society and other stakeholders.

Further information regarding the design, processes, reporting and more related to AVMA can be found here: <https://www.gavi.org/programmes-impact/types-support/regional-manufacturing-strategy/avma>

AVMA Monitoring, Evaluation and Learning (MEL) Framework

The AVMA MEL Framework’s development and subsequent approval by the Board represents a comprehensive review and approval of the AVMA Theory of Change (ToC) and monitoring plans.[[1]](#footnote-2) Immediate outcomes (to be realized within 2024 – 2026) primarily aim to signal the incentive design of the AVMA to existing and new manufacturers – encouraging a diverse landscape, especially across drug substance (DS) platforms. Mid-term outcomes (to be realized within 2027 – 2029) assume the support of Fill and Finish (F&F) manufacturers through accelerator payments and the disbursement of milestone payments to DS manufacturers. The resulting hypothesized long-term outcomes, which build on technical and operational AVMA components, are sustainable vaccine manufacturing, positive externalities in pandemic response, sustained market health, and diversified platform portfolio. For a more complete description of immediate, mid-term and long-term outcomes, please see the AVMA MEL Framework, which is available on the Gavi website. [[2]](#footnote-3) Considerations and options for refining outcomes in relation to evaluability and within the MEL framework are in scope of this evaluability assessment.

A screenshot of a diagram

AI-generated content may be incorrect.**Figure 1:** AVMA Theory of Change

AVMA’s learning agenda objectives[[3]](#footnote-4) include assessing AVMA’s contribution, outcomes and impact. Examining the relationship between AVMA and outcomes of interest will require data collection across AVMA’s lifespan. The EA is intended to help provide clear guidance on how to ensure robust assessment of AVMA’s influence on market evolution, investors and manufacturers' decision-making, and vaccine production capacity expansion through the use of evaluation methods and approaches, including counterfactual analysis if that is deemed appropriate, as well as clarifying data collection to be prioritised to facilitate the end-line evaluation.

Table 1 provides an overview of AVMA’s Monitoring, Evaluation and Learning (MEL) framework’s components, timing and focal points within the secretariat.

**Table 1**: Overview of MEL Framework components

|  |  |  |  |
| --- | --- | --- | --- |
| Year | MEL Framework component | M, E or L? | Degree of independence |
| 2025-2035 | **Biannual reporting**- operational key metrics (e.g. milestone payments and disbursement volumes) | M | **Modest**: Compiled by Secretariat, but per Board approved MEL framework (with clarity on data sources, definitions and limitations) |
| 2025-2035 | **Annual reporting**- all metrics in the AVMA logframe, with associated narrative (highlighting some key learnings) | M, L | **Modest**: Compiled by Secretariat, but per Board approved MEL framework (with clarity on data sources, definitions and limitations) |
| 2027, 2030, 2033 | **Triennial review**- (i) External review of the AVMA against its objectives, testing the Theory of Change and instrument outcomes  (ii) Informs a course correction report | M, E, L | **Medium**: External supplier |
| not before 2035 | **End-line evaluation** - Endline evaluation for accountability and learning | E, L | **High**: External supplier |

The end-line evaluation of AVMA is expected to build on all relevant components of the AVMA MEL framework, and particularly the triennial reviews. Triennial reviews represent a strong commitment to both learning and evidence-informed course correction over the life course of AVMA. These reviews will 1) review the causal pathways, key assumptions and relevance as laid out in the AVMA TOC; 2) summarize key progress against MEL framework metrics - interrogating why AVMA may be on or off track against these and proposed targets; 3) analyze key challenges, barriers and the broader ecosystem - to reflect on key risks and mitigations of relevance to ensure AVMA is on track for intended impact. Each triennial review will inform the generation of an associated course-correction report.

**Table 2**. High-level overview of MEL inputs, by MEL phase

|  |  |
| --- | --- |
| MEL phase | Description (MEL inputs) |
| Baseline | Established as part of the MEL framework, complemented by multiple inputs [[4]](#footnote-5) |
| Process | Triennial reviews (reassess ToC assumptions and causal pathways) |
|  |
| Outcomes | Triennial reviews and AVMA MEL Framework |  |
|  |
| Endline | Summative evaluation, including an assessment of contribution, outcomes and impact |  |

**Key audiences and users of AVMA MEL**

A diagram of a company

AI-generated content may be incorrect.The Gavi Board is the ultimate oversight and decision-making body for AVMA. Additionally, two advisory forums assist with AVMA's implementation and ensure the two-way information flow required for its smooth operation: the AVMA Investors Forum and the African Vaccine Manufacturing Forum. Figure 2 provides an overview of the AVMA governance structure.

Figure 2: AVMA governance structure

The roles of the bodies involved in AVMA are outlined in the table below[[5]](#footnote-6). Those in green (5 & 6) are advisory only. AVMA MEL outputs (annual reporting, triennial reviews, course correction reports and the final endline evaluation) will benefit from inputs from the Manufacturing Forum, and be reviewed and / or made available by Gavi governance as well as the AVMA Investor Forum.

|  |  |
| --- | --- |
| 1. Gavi Alliance Board | * Oversee AVMA as program, including annual reporting and risk reporting * Ultimate decision-making power, including final decision on strategic course corrections |
| 2. Programme and Policy Committee (PPC) | * Review programmatic proposals for the AVMA that require decisions by the governing bodies, particularly in relation to planned strategic course corrections * Receive regular updates on the AVMA from the Secretariat as part of Gavi annual reporting |
| 3. Audit and Finance Committee (AFC) | * Review and monitor AVMA financial reporting as part of Gavi’s financial management and corporate reporting * Oversee, review and monitor AVMA risk reporting as part of the enterprise risk management system |
| 4. Investment Committee (IC) | * Review and approve the asset allocation / investment strategy for the final long term treasury solution (if required) |
| 5. AVMA Investors Forum | * Review and comment on AVMA annual operational and risk reporting * Provide insights on investor priorities related to AVMA’s strategic direction and input on strategic prioritisation of investments * Review AVMA strategic course correction proposals * Review and comment the AVMA final evaluation report |
| 6. African Vaccine Manufacturing Forum | * Bring together key stakeholders from across the African Regional Manufacturing ecosystem. * Foster collaboration and high-level engagement across sectors and initiatives within the African vaccine manufacturing ecosystem, including AVMA. * Provide insights to inform the AVMA’s triennial review, including learning agenda related to dependencies |

## Objectives of the Evaluability Assessment for AVMA’s endline evaluation

While AVMA’s endline evaluation is not expected to take place before 2035, the Secretariat would like to ensure that data collection and complementary work that may be required to ensure a robust endline evaluation are identified and implemented over the coming years. [[6]](#footnote-7)

The evaluability assessment (EA) is expected to provide clear options for the endline evaluation’s robust assessment of contribution, outcomes and impact, detailing the rationale, limitations, and data collection and data structure requirements for each option. The Secretariat will consider this guidance and make updates to its data collection and MEL related work as required.

The EA for AVMA’s endline evaluation aims to:

1. describe and justify an evaluation approach and methodology that is best suited to evaluate AVMA’s contribution, outcomes and impact as of 2035, including assessing the options and considerations as well as methods for a counterfactual comparison if that is deemed appropriate, to enable a robust outcome and impact evaluation at endline. The EA will identify any data additional to that which will be collected per the AVMA MEL framework required to evaluate contribution, outcomes and impact on AVMA Impact Objective A: a sustainable, African vaccine manufacturing base, that is contributory to healthy global vaccine markets; and on AVMA Impact Objective B: improved African pandemic and outbreak vaccine supply resilience. It should provide suggestions on how these data can be best collected and analysed (recognising potential cost implications, risks, mitigating factors, and other aspects of feasibility).
2. identify how to ensure optimal linkages of the triennial reviews to best prepare for the endline evaluation.

It is important to note that the EA is not required to assess the Board-approved AVMA Theory of Change (ToC) and monitoring plans. Rather, the EA will review Board-approved AVMA MEL framework to identify anything that may be missing, or that may require further elaboration, to support a quality and robust endline evaluation that is able to assess contribution, outcomes and impact.

## *I. Scope of Work*

The requirement involves the following key activities:

* Review of key documents shared by Gavi, not expected to exceed 30 documents.
* Conduct targeted key informant interviews (KII) or focus group discussions, including with Gavi’s AVMA team and key partners, not expected to exceed 10 KIIs / focus group discussions.
* Propose and justify one or more evaluation approach(es), methods, and key considerations to enable a robust end line evaluation of AVMA contribution, outcomes and impact; including options and considerations as well as methods for a counterfactual comparison if that is deemed appropriate to enable a robust outcome and impact evaluation at endline. Justifications should explain why the specific proposed approach and methods are best suited to achieve the objective of evaluating AVMA’s impact at endline and may include a targeted literature review and/or simulation modelling.
* Identify and describe (if any) limitations to the proposed approach and method(s)as well as measures that will be taken to address or mitigate against these limitations. Outline the risks associated with the proposed approach and method(s) and the mitigation measures that will be implemented to address these risks.
* Provide suggestions for the consistent structuring of existing data that will be collected per the AVMA MEL framework to enable endline evaluation impact analysis. Identify and justify whether data collection is required in addition to what will be collected and analyzed under the AVMA MEL Framework, including a detailed data collection and analysis plan as well as forecast cost implications, risks, mitigating factors, and other aspects of feasibility, as relevant.
* Provide guidance to ensure optimal linkages between the triennial reviews and the endline evaluation, and how these reviews can best support a robust endline evaluation assessing impact.

**Expected Deliverables and Timelines:**

The following deliverables shall be produced by completing these tasks:

* Inception report and summary slides (.ppt), including:
  + Description of approach and methods that will be used for the evaluability assessment, inc. potential targeted literature review and simulation modelling.
  + Initial analysis to determine options and key considerations of evaluation approach(es), methods to enable a robust end line evaluation of AVMA contribution, outcomes and impact.
* Draft report and summary slides (.ppt)
  + (i) clear justification (advantages, limitations) for one or more evaluation approach(es), methods, and key considerations to enable a robust end line evaluation of AVMA contribution, outcomes and impact.
  + (ii) targeted literature reviews, simulation modelling, other analysis to support justification, if relevant.
  + (iii) detailed description of proposed evaluation approach, methods and key considerations; including a description of limitations to the proposed approach and method(s), if any, as well as measures that will be taken to address or mitigate against these limitations. Outline the risks associated with the proposed approach and method(s) and the mitigation measures that will be implemented to address these risks.
  + (iv) a data analysis plan of data that is not planned to be collected per the AVMA MEL framework, but would be required to undertake a robust endline evaluation, including data collection form(s), if relevant; and
* (v) a description of options to ensure optimal linkages among the triennial reviews, describing how these can best support a robust endline evaluation assessing impact
* Final report and summary slides (.ppt); participation in dissemination events.

The scope of work is expected to be finalized at a maximum of **50 working days, spread from September 2025 to January 2026** (depending on launch date, noting summer schedules).

|  |  |
| --- | --- |
| **Illustrative Time Allocation** | |
| Task | Max. days |
| **Inception Report and summary slides** | |
| Desk review | 3-5 |
| Develop guide for key informant interviews (KIIs) and focus group discussions | .5 |
| Coordinate and conduct KIIs (10 KIIs at max 3 per day) | 4-5 |
| Coordinate and conduct Focus Group discussion | 2 |
| Analysis, including potential targeted literature review, simulation modelling, other, to inform options and key consideration. | 5-10 |
| Production of inception report (15 pages max + slide deck + Annexes) | 10 |
| Collate and coordinate follow-up to questions and comments as needed | 2 |
| Incorporate comments and produce revised draft | 2-5 |
| **Draft Report and summary slides** | |
| Production of draft report and slides | 3 |
| Collate and coordinate follow-up to questions and comments as needed needed | 2 |
| Incorporate comments and produce revised draft | 2-5 |
|  | |
| **Final Report and summary slides** | |
| Production of final report and slides | 3-5 |
| Delivery of final report and slides | 1 |

**Qualification Requirements:**

The bidder should:

* Submit a Cover Letter containing the following:
  + Name and address of the Service Provider
  + Name, title, telephone number, and e-mail address of the person authorized to commit the Service Provider to a contract
  + Name, title, telephone number, and e-mail address of the person to be contacted regarding the content of the proposal, if different from above
  + A signature of this letter is done by a duly authorized representative of your company
* Demonstrate understanding of the requirements and deliverables
* Have the ability to work with deadlines in a challenging working environment.
* Demonstrate strong past experience with similar services
* Fluency in written and spoken English
* Have excellent presentation and communication skills.
* Experience with evaluation methods and practices focused on economic, outcome, and impact evaluations. Experience in evaluating complex multi-year programmes. Subject matter expertise in economics, finance, private sector development, impact investing, market shaping and vaccine markets, including in the African context, is highly desired.
* Demonstrated track record in designing, collecting and interpreting data from evaluability assessments to produce an actionable report to strengthen endline impact evaluations.

1. **RFQ Rules and Procedures**

Gavi’s Request For Quotation rules will apply for this bidding process and work against the below timelines:

|  |  |  |  |
| --- | --- | --- | --- |
| **Event** | | **Responsible Party** | **Timeline** |
| 1. | Launch Invitation to bid | Gavi | 09-Jul-25 |
| 2. | Intent to Participate and Q&A submitted to Gavi | Service Provider | 16-Jul-25 |
| 3. | Q&A responses | Gavi | 23-Jul-25 |
| 4. | Proposals submitted | Service Provider | 11-Aug-25 |
| 5. | Selection | Gavi | 18-Aug-25 |
| 6. | Shortlisted Interview [TBC] | Gavi & Service Providers | TBC |
| 7. | Contract drafting | Gavi & Service Provider | 25-Aug-25 |
| 8. | Estimated Contract Start date | Gavi & Service Provider | 12-Sep-25 |

The bidder should:

* Submit a Cover Letter containing the following:
  + Name and address of the Service Provider
  + Name, title, telephone number, and e-mail address of the person authorized to commit the Service Provider to a contract
  + Name, title, telephone number, and e-mail address of the person to be contacted regarding the content of the proposal, if different from above
  + A signature of this letter done by a duly authorized representative of your company

**Technical Quotation:**

Bidder’s must ensure that the Technical Quotation is provided within dedicated electronic document/file and that no financial information whatsoever is contained within. This is to ensure pricing information cannot be viewed when the Technical Quotation is under evaluation.

The technical Quotation should specify the following:

* CV of the person/s to implement the project detailing professional background and advanced knowledge of and experience with catalyzing private sector development and market shaping through complex innovative financial instruments, ideally in the SSA context. Experience of the bidder conducting evaluability assessments to inform appropriate, robust, and actionable design of outcome and impact evaluations. Experience undertaking evaluability assessments in Global Health Initiatives and other development funding entities is an asset. Strong subject matter and evaluation expertise and experience, ideally in the Sub-Saharan African (SSA) context, in outcome and impact evaluation approaches and methods (quantitative and qualitative), including: experience in designing and undertaking outcome and impact evaluation of financial instruments to catalyze private sector development and market shaping, ideally in SSA.
* a short proposal (10 pages max) outlining a good understanding of, and ability to meet, requirements and proposed deliverables. This includes a demonstrated understanding of scope of work and deliverables; and a robust, clear, appropriate, and coherent methodology proposed for undertaking the work; acknowledgement of the limitations of the methodology proposed / challenges of the proposed assessment, and an appropriate quality assurance plan.

**Financial Quotation**:

Bidders should submit a financial Quotation with a detailed breakdown of the fees and estimated expenses. Fees should be represented as a daily rate in USD equivalent.

**Evaluation:**

The following aspects will be considered for the evaluation of the submitted proposals:

* Quality and appropriateness of the overall proposal (completeness, clarity, presentation), including “Technical approach” (**40 points**).
* Suitability of the proposed approach and methodology including person/organisation’s capacity to undertake the services (understanding the needs of the assignment, appropriateness of the proposed methodology, acknowledgement of limits, and practicality and feasibility of the workplan), including “Expertise and Qualifications of proposed personnel” (**25 points**).
* Qualifications and experience of the individual/s or proposed team, including “Proposed team structure” (**5 points**).
* Best Value for Money considering the Lowest priced technically compliant of the proposed offers. (**30 points**).
  + Please note that prices should be tendered in United states Dollars (USD). Prices submitted in any other currency will be evaluated based on the Gavi prescribed exchange rate of the closing of the bid date as the financial evaluation of the bids is completed in USD.  Final contractual payments will be agreed by the parties during contract negotiations and can be made in the following Gavi accepted currencies:
* United states Dollars (USD)
* Swiss Francs (CHF)
* Euros (EUR)
* Australian Dollars (AUD)
* Canadian Dollars (CAD)
* British Pounds (GBP)
* Norwegian Krone (NOK)
* Japanese Yen (JPY)

Proposals that will obtain a score of **70 points** and higher will be invited to the interview (TBC). The contract will be awarded to the lead proposal based on the outcome of both assessments.

**Quotation Submission:**

Interested bidders should declare their Intent to Participate as well as any potential Conflict of Interest by registering online using the: [Gavi Supplier Declaration Form](https://app.azavista.com/w/event/66f94f88722759dc131a802f?clear=true) no later than 16-Jul-25 at 23:59 (CET)

Interested bidders, who submitted their Intent to Participate, should send their questions no later than 16-Jul-25 at 23:59 (CET) using the following email address: [procurement@gavi.org](mailto:procurement@gavi.org) and the template below:



Technical and Financial Proposals should be sent no later than **11-Aug-25** at 23:59 (CET) at the following email address: [procurement@gavi.org](mailto:procurement@gavi.org)

Please ensure that the different Proposal elements are returned in either MS Office Format or PDF.

**Submission Checklist:**

|  |  |  |  |
| --- | --- | --- | --- |
| Document Checklist | | | |
| ☐ | Cover Letter which includes:   * Name and address of the Service Provider * Name, title, telephone number, and e-mail address of the person authorized to commit the Service Provider to a contract * Name, title, telephone number, and e-mail address of the person to be contacted regarding the content of the proposal, if different from above * A signature of this letter done by a duly authorized representative of your company | | |
| ☐ | Technical Quotation | ☐ | Financial Quotation |
| ☐ | Pricing Schedule Template (if applicable) | ☐ | [Gavi Supplier Declaration Form](https://app.azavista.com/w/event/66f94f88722759dc131a802f?clear=true) |

## Request For Quotation Rules:

Gavi invites you to submit a competitive bid by responding to this “Request for Quotation” (RFQ), based on the below outlined rules:

1. This entire RFQ and all related discussions, meetings, exchanges of information, and subsequent negotiations that may occur are confidential.
2. The issuance of this RFQ in no way commits Gavi to make an award. Gavi is under no obligation to justify the reasons for its supplier(s) choices as a result of this RFQ. Gavi may choose not to justify its business rewarding decision to the participants to this tender.
3. Gavi reserves the right to:

* reject any proposal without obligation or liability to the potential bidder;
* withdraw this RFQ at any time before or after submission of bids, without prior notice, explanation or reason.
* accept other than the lowest price offer;
* award a contract on the basis of initial offers received, without discussions or requests for best and final offers;
* decide not to award any contract to any bidder responding to this RFQ,

1. You agree that your bid is valid for no less than sixty (60) days from the quotation due date.
2. Faxed copies will not be accepted. Late quotations are subject to rejection.
3. Gavi reserves the right to request additional data, information, discussions or presentations to support part of, or your entire bid proposal. Bidders or their representatives must be available to discuss the details of their proposal during the evaluation process.
4. All responses should be submitted in electronic version.
5. The proposed time plan set out above indicates the process Gavi intends to follow. If there are any changes to this time plan, Gavi will notify you in writing.
6. If the applicant is a US Citizen or resident (Green Card holder) or a non-US person living or working in the US, they should be aware of OFAC regulations.

1. [↑](#footnote-ref-2)
2. See [Board-2024-Mtg-02-Doc 11b-Annex B:](https://www.gavi.org/sites/default/files/board/minutes/2024/6-7-june11b%20-%20Annex%20B%20-%20AVMA%20Monitoring%2C%20Evaluation%20and%20Learning%20Framework.pdf) https://www.gavi.org/sites/default/files/board/minutes/2024/6-7-june11b%20-%20Annex%20B%20-%20AVMA%20Monitoring%2C%20Evaluation%20and%20Learning%20Framework.pdf Ibid. [↑](#footnote-ref-3)
3. [ibid.](file:///C:/Users/ngons/OneDrive%20-%20Gavi/Documents/_NG%20Working%20Files/__AVMA/11b%20-%20Annex%20B%20-%20AVMA%20Monitoring,%20Evaluation%20and%20Learning%20Framework.pdf) [↑](#footnote-ref-4)
4. Planned inputs to monitoring the baseline of the ecosystem in which AVMA operates includes the upcoming Ecosystems Review (to be commissioned in 2026, which will feed into the Triennial Review); substantial sector specific analytical work commissioned as part of AVMA’s design, including a key dependencies review, and the outcome reports from Annual Manufacturers’ Forums. [↑](#footnote-ref-5)
5. Please note the Investment Committee (IC) is not included in the governance schematic, as IC can provide guidance on the investment strategy for the long-term treasury solution – but only if required. [↑](#footnote-ref-6)
6. See also, questions from Evaluation Advisory Committee September 2024. [↑](#footnote-ref-7)